# Diagnostic Performance of the QIAstat‐Dx Meningitis/Encephalitis Panel: Insights From Seven Clinical Evaluations

## TL;DR

The QIAstat-Dx Meningitis/Encephalitis Panel is a rapid diagnostic tool for central nervous system infections, showing strong performance in detecting pathogens from cerebrospinal fluid.

## Contribution

The study provides a comprehensive review of the diagnostic performance of QIAstat-Dx across seven evaluations, highlighting its strengths and limitations compared to existing panels.

## Key findings

- The QIAstat-Dx panel demonstrated high positive percent agreement (90.6% to 100%) in detecting pathogens from CSF samples.
- Comparisons with the BioFire FilmArray panel showed minimal performance variation, supporting QIAstat-Dx as a robust diagnostic tool.
- Limitations include low detection rates for certain targets like Mycoplasma pneumoniae and herpesviruses such as HSV-1.

## Abstract

Central nervous system (CNS) infections require prompt and accurate diagnosis to enable timely and targeted antimicrobial therapy. Syndromic PCR‐based assays, such as the QIAstat‐Dx Meningitis/Encephalitis Panel (QIA‐ME), allow rapid detection of key pathogens directly from cerebrospinal fluid (CSF). We conducted a narrative review of seven studies (2023–2025) evaluating the diagnostic performance of QIA‐ME. A total of 1007 clinical CSF samples, ranging from 5 to 585, were retrospectively analyzed, with 8 to 14 targets assessed per study. Positive percent agreement (PPA) ranged from 90.6% to 100%, while negative percent agreement (NPA)—available in only three studies—ranged from 75.0% to 97.7%. In three studies, head‐to‐head comparisons with the BioFire FilmArray Meningitis/Encephalitis Panel (FA‐ME) revealed minimal variation in performance, reinforcing the robustness of QIA‐ME. However, target‐specific limitations were noted, particularly for herpesviruses such as HSV‐1. Methodological heterogeneity across studies—in terms of design, comparator methods, and sample size—limits generalizability. The exclusion of cytomegalovirus and inclusion of Mycoplasma pneumoniae and Streptococcus pyogenes in the QIA‐ME panel raise concerns about the clinical utility of low‐prevalence targets, especially as M. pneumoniae was not detected in any clinical sample. Despite these limitations, the integration of amplification curve analysis and the strong concordance with FA‐ME support QIA‐ME as a valuable tool for CNS infection diagnostics. Prospective real‐world studies are warranted to clarify the clinical value of individual targets and guide appropriate use across varied patient settings.

This review compares the QIAstat‐Dx ME panel with the BioFire FilmArray ME panel across seven studies on CNS infections. The findings support the clinical utility of QIAstat‐Dx, highlighting its diagnostic performance, interpretative advantages, and the need for further real‐world evaluation in high‐risk populations.